FDA allows imports of syphilis drug alternate during shortage
时间:2024-06-26 12:39:55 阅读(143)
US regulators gave temporary permission for importation of a form of penicillin used to treat syphilis amid a national shortage of Pfizer Inc.’s version of the drug along with a dramatic increase in cases.
The Food and Drug Administration authorized importation of penicillin G benzathine made by a French company, Laboratoires Delbert, according to the agency website. Pfizer’s Bicillin L-A, the only version of the drug available in the US, has been in short supply since April.
While as little as one injection of penicillin G benzathine can cure syphilis, the shortage prompted US health officials to recommend giving some patients doxycycline, another antibiotic therapy that requires of weeks of twice-daily pills. The long treatment regimen raises the risk that patients might not complete it, leaving them sick and potentially infectious to others.
The National Coalition of STD Directors applauded the FDA’s action. “We hope this is the first step toward seeing a resolution to this shortage,” David Harvey, executive director of NCSD, said in a statement. Harvey had previously criticized the federal government’s response.
To fix the shortage, Pfizer has added manufacturing shifts and more than halved production time. The company has invited customers who are having trouble getting the drug to contact them directly. “We continue to supply the market above historical rates, and we are reserving product for emergency needs,” a Pfizer spokesperson said.
The shortage is estimated to last through June, according to the FDA.
Unlike Pfizer’s prefilled syringe, Laboratoires Delbert’s formulation of the drug is a powder that must be mixed and then injected by a health-care provider.
猜你喜欢
- Curb excessive trading in derivatives- Sebi may mandate stricter risk profiling
- Nifty’s June target at 15,700, Bank Nifty may hit 36,200 soon; BFSI, auto stocks may outrun
- Jefferies raises concerns about India valuations, puts Buy on Axis Bank, Hold on Havells
- Nifty to reclaim 17,200 or bears to grip D-St- Check crude oil, US markets, FII data, more before market opens
- Compliance, tax major challenges for direct listing abroad
- Crude oil rises on supply concerns, China demand outlook brightens
- JP Morgan bullish on LIC, sees 29% rally despite steep fall since listing; says D-Street mispricing stock
- Nifty to test 18400 again or bears to drag index below 18100- 7 things to know before market opening bell
- Coal India share price tanks 3% after Q4 net profit falls nearly 18%; Should you buy, sell or hold-